<PAGE>   1
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934

                             For the quarterly period ended June 30, 2001

         TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                             For the transition period from        to
                                                            ------    ------

                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


                  DELAWARE                                    73-1461841
         (State or other jurisdiction of                     (IRS Employer
         Incorporation or organization)                    Identification No.)

                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)

                                 (713) 779-3663
                           (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes [ ] No [ ]


                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of June 30, 2001, there were 3,516,895 shares of Common Stock, par value
$0.001 per share, outstanding.

Transitional Small Business Disclosure Format (Check one): Yes [ ] No [X]

================================================================================

<PAGE>   2


                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                      FOR THE QUARTER ENDED JUNE 30, 2001.


Part I   Financial Information (unaudited)

<Table>
<Caption>
                                                                                    Page
<S>               <C>                                                               <C>
       Item 1.    Financial Statements

                      Balance Sheet.............................................    1

                      Statements of Operations..................................    2

                      Statements of Cash Flows..................................    3

                      Notes to Financial Statements.............................    4

       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations.................    7

Part II  Other Information......................................................    9

       Item 1.    Legal Proceedings.............................................    9

       Item 2.    Changes in Securities.........................................    9

       Item 3.    Defaults Upon Senior Securities...............................    9

       Item 4.    Submission of Matters to a Vote of Security Holders...........    9

       Item 5.    Other Information.............................................    9

       Item 6.    Exhibits and Reports on Form 8-K..............................    9

Signatures......................................................................    11
</Table>


                                       i
<PAGE>   3



                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET

<Table>
<Caption>
                                                                                June 30, 2001
                                                                                -------------
                                                                                 (Unaudited)
<S>                                                                             <C>
ASSETS
Current assets:
             Cash and cash equivalents                                          $     545,668
             Accounts receivable (net)                                          $     977,244
             Due from related parties                                           $       8,400
             Work-in-process                                                    $      72,847
             Prepaid expenses                                                   $      56,527
                                                                                -------------
Total current assets                                                                1,660,686

Property and equipment, net                                                         1,352,430
Other assets, net                                                                      13,641
                                                                                -------------
Total assets                                                                    $   3,026,757
                                                                                =============

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
             Accounts payable                                                   $     491,974
             Due to related parties                                             $      17,065
             Notes payable                                                      $     367,940
             Capital lease obligations-current portion                          $     185,801
             Accrued expenses                                                   $     235,816
             Customer deposits                                                  $     449,762
                                                                                -------------
Total current liabilities                                                       $   1,748,358

Note payable-long term portion                                                         51,111
Capital lease obligations-long term portion                                           365,624
Deferred rent expense                                                                  18,540
                                                                                -------------
Total Liabilities:                                                                  2,183,633

Stockholders' equity
             Preferred stock, $0.001 par value:
                  Authorized shares - 2,000,000
                  None issued and outstanding
             Common stock, $0.001 par value:
                  Authorized shares - 8,000,000
                  Issued shares:3,521,395 and outstanding shares:3,516,895              3,521
             Additional paid-in capital                                             2,670,343
             Treasury Stock at cost                                                    (4,946)
             Accumulated comprehensive loss                                            (2,811)
             Accumulated deficit                                                   (1,822,983)
                                                                                -------------
Total stockholders' equity                                                            843,124
                                                                                -------------
Total liabilities and stockholders' equity                                          3,026,757
                                                                                =============
</Table>


See accompanying notes to the financial statements.


                                       1
<PAGE>   4


                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF OPERATIONS


<Table>
<Caption>
                                                   Three months Ended June 30,      Six months Ended June 30,
                                                   ----------------------------    ----------------------------
                                                       2000            2001            2000            2001
                                                   ------------    ------------    ------------    ------------
                                                            (Unaudited)                     (Unaudited)
<S>                                                <C>             <C>             <C>             <C>
Revenue:
          Laboratory Services                      $  1,484,134    $  1,859,917    $  2,685,927    $  3,079,792

Costs and expenses:
          Costs of services                             951,941       1,343,874       1,702,687       2,311,482
          Sales, general and administrative             482,951         506,709         926,148       1,072,072
                                                   ------------    ------------    ------------    ------------
Total costs and expenses                              1,434,891       1,850,583       2,628,835       3,383,554
                                                   ------------    ------------    ------------    ------------
Operating income (loss)                                  49,243           9,334          57,092        (303,762)

Other income and (expense):
          Interest income                                 4,693           5,549           5,328          14,396
          Forfeited deposit                                   0         125,323               0         125,323
          Interest expense                              (16,778)        (14,505)        (37,024)        (28,770)
                                                   ------------    ------------    ------------    ------------
Total other income (expense)                            (12,085)        116,367         (31,696)        110,949
                                                   ------------    ------------    ------------    ------------
Income before income taxes                               37,157         125,701          25,396        (192,813)

Provision for income taxes                                    0               0               0               0
                                                   ------------    ------------    ------------    ------------
Net income                                         $     37,157    $    125,701    $     25,396    ($   192,813)
                                                   ============    ============    ============    ============

Basic income (loss) per common share                       0.01            0.04            0.01           (0.05)
Diluted income (loss) per common share                     0.01            0.03            0.01           (0.05)
</Table>


See accompanying notes to the financial statements.

                                       2
<PAGE>   5



                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS


<Table>
<Caption>
                                                                   Six Months ended June 30,
                                                                   -------------------------
                                                                      2000           2001
                                                                   ----------     ----------
                                                                           (Unaudited)
<S>                                                                <C>            <C>
OPERATING ACTIVITIES
Net loss                                                           $   25,396     $ (192,813)
Adjustments to reconcile net loss
   to net cash provided by (used in) operating activities
               Depreciation and amortization                          171,059        209,055
               Provision for bad debts                                     --          9,574
               Changes in operating assets and liabilities:
                    Accounts receivable                               105,604       (160,615)
                    Work-in-process and finished goods                  1,692        193,420
                    Prepaid expenses                                   18,069         39,436
                    Other Assets                                        1,172              0
                    Due to/from related parties                            --          3,517
                    Accounts payable                                 (174,286)       (26,546)
                    Accrued expenses                                  (61,795)       118,800
                    Deposits                                          285,599       (548,920)
                                                                   ----------     ----------
Net cash provided by (used in) operating activities                   372,509       (355,092)

INVESTING ACTIVITIES
Purchases of property and equipment                                  (130,563)       (75,940)
                                                                   ----------     ----------
Net cash used in investing activities                                (130,563)       (75,940)

FINANCING ACTIVITIES
Proceeds from issuance of notes payable                               106,500         92,000
Principal payments on notes payable                                  (187,252)       (63,361)
Principal payments on capital leases                                 (132,821)       (45,993)
Proceeds from exercised stock options                                 135,641            730
Proceeds from exercised warrants                                       12,500             --
Redemption of warrants                                                (31,250)            --
                                                                   ----------     ----------
Net cash provided by financing activities                             (96,682)       (16,624)
                                                                   ----------     ----------
Net increase (decrease) in cash and cash equivalents                  145,264       (447,656)
Cash and cash equivalents at beginning of period                      270,830        993,324
                                                                   ----------     ----------
Cash and cash equivalents at end of period                         $  416,095     $  545,668
                                                                   ==========     ==========
</Table>


See accompanying notes to the financial statements.

                                       3
<PAGE>   6


                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)


1.       ORGANIZATION

         Lark Technologies, Inc., a Delaware corporation (the "Company"), was
formed on November 16, 1994, as a wholly-owned subsidiary of SuperCorp Inc.
("SuperCorp"), for the purpose of merging with Lark Sequencing Technologies,
Inc., a Delaware corporation ("Sequencing"), as outlined in a merger agreement
("Merger Agreement") entered into by SuperCorp and Sequencing on October 28,
1994. SuperCorp approved the Merger Agreement on September 5, 1995 and by the
stockholders of Sequencing on September 12, 1995. As a consequence of the
merger, all of the shares of common and preferred stock of Sequencing were
exchanged for 1,800,000 shares of Common Stock of the Company with a par value
of $0.001 per share and the 200,000 shares of Common Stock of the Company held
by SuperCorp were distributed to the shareholders of SuperCorp. The Company has
succeeded to all of the business previously undertaken by Sequencing. Lark
provides specialized laboratory services for DNA sequencing to biotechnology
researchers.

2.       ACCOUNTING POLICIES

Basis of Presentation

         The accompanying unaudited interim financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information in footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to these rules and
regulations. The accompanying unaudited interim financial statements reflect all
adjustments which the Company considers necessary for a fair presentation of the
results of operations for the interim periods covered and for the financial
condition of the Company at the date of the interim balance sheet. All such
adjustments are of a recurring nature. Results for the interim periods are not
necessarily indicative of results for the year.

         For financial reporting purposes, the merger of the Company and
Sequencing has been accounted for as a recapitalization of Sequencing, and the
historical financial statements of Sequencing prior to the merger became the
financial statements of the Company.

Recently Issued Accounting Standards

In June 1998, the Financial Accounting Standards Board issued Statements of
Financial Accounting Standards No.133, Accounting for Derivative Financial
Instruments and Hedging Activities ("SFAS No.133"). SFAS No.133 requires that
all derivatives be recognized as assets and liabilities and measured at fair
value. The accounting for changes in the fair value of a derivative depends on
the intended use of the derivative and the resulting designation. SFAS No.133,
as amended, is effective for the fiscal years beginning after June 15, 2000 and
early adoption is permitted. Because of the Company's minimal use of
derivatives, management does not anticipate that the adoption of SFAS No.133
will have a significant effect on net income or the financial position of the
Company.

3.       INVENTORY

         Work in process inventory includes the direct and indirect costs
associated with projects that had been started but not yet completed at June 30,
2001. Direct costs include such items as the cost of labor, reagents and
supplies directly associated with each project. Indirect costs include such
items as general supplies, laboratory management, depreciation, and costs to
operate the lab. These costs are applied to each project on the basis of direct
labor hours incurred for the project, up to the point of measurement, such as
the end of an accounting period. At June 30, 2001, work in process inventory was
$72,847. During the quarter, the Company wrote-off $149,656 of finished goods
inventory deemed not saleable by management.


                                       4
<PAGE>   7


4.       NOTES PAYABLE

         On December 7, 2000, the Company renewed its revolving line of credit
and extended the maturity to December 31, 2001. Under the terms of its revolving
line, the Company may borrow up to $600,000 at the bank's prime rate (6.5% at
June 30, 2001) plus 2%. The borrowing base of this line of credit is equal to
80% of certain accounts receivable that are no more than 90 days old. On June
30, 2001 the Company had $323,955 outstanding under this line. Under the terms
of the revolving line of credit agreement, the Company is required to maintain
certain financial ratios and a specific level of net worth. As of June 30, 2001,
the Company was not in compliance with some of the required financial ratios and
has obtained a statement from the bank waiving the missed requirements until
September 1, 2001. The bank has placed a restriction on further advances on the
line during the term of the waiver. Management expects the Company will return
to compliance with the required financial ratios on or before September 1, 2001.

         On March 13, 1998, the Company arranged an advised discretionary credit
line for the financing of equipment with the same bank used for the line of
credit described above. Under the terms of this discretionary credit, the
Company was able to borrow up to $600,000 secured by the equipment purchased
with the proceeds of the borrowings. This discretionary credit line provided for
the borrowings of up to 75% of the purchase price of equipment at the bank's
prime plus 1.5%. This credit line provided for repayment terms up to 36 months
and matured on May 31, 1999. On January 5, 1999, the Company borrowed $22,000
against this line of credit for the purchase of lab equipment. As of June 30,
2001, a balance of $4,278 remained on this loan.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, 2001 the company
borrowed $92,000 under this facility. On that same day, the advance line feature
of this loan converted to a fixed facility requiring monthly payments over a 36
month period at the bank's prime rate plus 2%. As of June 30, 2001, a balance of
$81,778 remained on this loan.

         On March 29, 2001, the Company entered into a capital lease for the
purchase of two additional automated DNA sequencers that cost approximately
$263,000. Under the terms of the 36 months lease, the Company may purchase this
equipment for a nominal amount at the end of the lease.

         On April 3, 2001, the Company entered into a capital lease for the
purchase of a Multiprobe robotic liquid handling system that cost approximately
$76,000. Under the terms of the 60 months lease, the Company may purchase this
system for a dollar at the end of the lease.

         On June 20, 2001, the Company's U.K. office entered into a capital
lease for the purchase of an automated DNA sequencer that cost approximately
$146,000. Under the terms of the 36 months lease, the Company will become the
owner of the goods at the end of the lease.

5.       EARNINGS PER SHARE

                  The following table sets forth the weighted average shares
outstanding for the computation of basic and diluted earnings per share:


<Table>
<Caption>
                                                  For the three months ending        For the six months ending
                                                             June 30,                           June 30,
                                                     2000             2001             2000             2001
                                                  ----------       ----------       ----------       ----------
<S>                                               <C>              <C>              <C>              <C>
Weighted average common shares outstanding:        3,478,804        3,516,895        3,433,046        3,516,680
Dilutive securities - employee stock options:       179,007           93,912           249,384          106,784
                                                  ----------       ----------       ----------       ----------
Weighted average common shares outstanding
 Assuming full dilution:                           3,657,811        3,610,807        3,682,430        3,623,464
                                                  ==========       ==========       ==========       ==========
</Table>


                                       5
<PAGE>   8


         Options to purchase 455,440 shares of common stock were outstanding
during 2001 but were not included in the computation of diluted earnings per
share because the effect would be antidilutive.

6.       COMMITMENTS AND CONTINGENCIES

Stock Options and Warrants

         During the quarter, no options or warrants were exercised.

Patent License Agreement

         Effective June 15, 1995, the Company entered into an exclusive patent
sub-license agreement with another biotech company. The agreement grants to the
Company an exclusive license to certain "Licensed Patent Rights" of this third
party and requires the Company to perform research and development efforts as
defined in the agreement. The Company is required to pay the third party a
royalty of 25% to 50% of all consideration the Company receives as a result of
sales of licensed products and licensed processes or a sub-license or assignment
of the Company's rights under the agreement. If the Company does not meet the
research and development milestones as defined in the agreement, or is unable to
successfully commercialize the results of the research and development efforts,
the agreement will terminate. Otherwise, the agreement will terminate upon the
dissolution of the Company or the expiration of the "Licensed Patent Rights".
The Company may also terminate the agreement with 60 days written notice to the
third party.

         The Company has written off $16,749 in other assets related to
"Licensed Patent Rights" as Management feels that the likelihood that these
patents will issue is highly unlikely.

Sponsored Research Contract

         On October 6, 1998, the Company announced the restructuring of its
senescence technology development program. Sennes Drug Innovations, Inc., the
Company's licensor for the senescence technology, which originated with a third
party, recently appointed a new president. This appointment was allowed by the
settlement of various technology transfer issues between the third party and
Sennes. This new president will represent the Sennes technologies, including the
senescence gene technology licensed to the Company, to third parties. The
Company's license for senescence technologies remains intact.

         The senescence technology includes genes involved in regulating the
four senescence gene pathways. Senescence is the normal physiological process
that controls cellular immortality. Immortal cells are closely related to cancer
and can add insights into aging and abnormal development.

Commitments and Contingencies

         The Company is involved in various legal proceedings that have arisen
in the ordinary course of business. In the opinion of management, based on
consultations with counsel and a review of the facts, the ultimate liability to
the Company will not have a material effect on the financial position of the
Company.


                                       6
<PAGE>   9


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
         OF OPERATIONS

         The following discussion and analysis should be read in conjunction
with the Financial Statements and the accompanying Notes herein, and is
qualified entirely by the foregoing and by other more detailed financial
information appearing elsewhere.

GENERAL

         Lark is a leading molecular biology Contract Research Organization
(CRO) providing services to the pharmaceutical and biotechnology industries
worldwide. Lark's service portfolio consists of various DNA sequencing and
molecular biology services as follows:

      o  Automated DNA Sequencing Services. Lark applies automated sequencing
         techniques to generate high throughput DNA sequence and fast turnaround
         screening information, including genome sequencing, shotgun sequencing
         and shotgun library construction services.

      o  Genetic Stability Testing Services. Lark's genetic stability testing
         services are used to characterize Master Cell Banks, Manufacturers'
         Working Cell Banks and PostProduction Cell Samples from bacterial,
         yeast and cell cultures. Genetic stability testing is used to analyze a
         production strain's stability and demonstrate that the expression
         system has not undergone any mutations or rearrangements that would
         affect the integrity of the product. This service assists companies
         producing genetically manufactured products to optimize production
         yields, determine product purity, and support regulatory submissions.
         This service was introduced in late 1996.

      o  Quantitative Polymerase Chain Reaction (PCR) Services. Lark uses
         Quantitative PCR techniques to measure the distribution and expression
         of target DNA or RNA in a customer's sample from cultured cells,
         microorganisms, or tissues such as brain, lung, liver, and kidneys.

      o  Array Services. Lark uses automated PCR techniques to produce molecular
         materials used in the construction of biochip arrays.

      o  Molecular Biology Services. Lark offers a variety of molecular biology
         services including library screening, library prescreening, southern
         blot analysis, subcloning, plasmid preparation and PCR amplification.
         Lark consults with its customers to customize a broad range of
         molecular biology projects.

         In 1995 Lark undertook a senescence gene discovery program for its own
account. Although several genes were discovered in this program, lack of gene
functionality coupled with license issues caused Lark to reduce its funding for
this program. Lark continues to work towards license issue resolution and
eventual potential sublicense agreements.

RESULTS OF OPERATIONS

         GROSS REVENUES. Gross revenues increased 25% from $1,484,134 to
$1,859,917 for the three-month periods ended June 30, 2000 and 2001,
respectively. Gross revenue increased 15% from $2,685,927 to $3,079,792 for the
six-month periods ended June 30, 2000 and 2001 respectively. The increase in
revenues for the quarter and six months was due to increases in the quick
turnaround and GMO segments of the Company's current business model.

         COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services increased 41% from $951,941 to $1,343,874
for the three-month periods ended June 30, 2000 and 2001, respectively. Costs of
services increased 36% from $1,702,687 to $2,311,482 for the six-month periods
ended June 30, 2000 and 2001, respectively. Approximately one-half of the
increase was due to the finished goods inventory of QPCR assays being written
down to zero as management deemed the assays to be unsaleable. The remaining
increase in costs of services was due to the additional variable costs required
to produce the additional revenue for the quarter, as well as, the development
costs required to enhance the Company's lab operation. These extra costs were
incurred to significantly increase operating efficiency of lab operations. See
variability of future operating results below for further details. Costs of

                                       7
<PAGE>   10


services as a percentage of revenue were 64% and 72% for the three-month periods
ending June 30, 2000 and 2001 respectively and 63% and 75% for the six-month
periods ended June 30, 2000 and 2001, respectively.

                  SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising. Sales, general and administrative expenses increased 5% from
$482,951 to $506,709 for the three-month periods ended June 30, 2000 and 2001,
respectively. The increase resulted from higher sales compensation costs
incurred by the addition of sales representatives in the northeastern U.S. and
the U.K., as well, as higher advertising expenses to promote the Company's
services. Sales, general and administrative expenses increased 16% from $926,148
to $1,072,072 for the six-month period ended June 30, 2000 and 2001,
respectively. Sales, general and administrative expenses as a percentage of
revenue were 33% and 27% for the three-month and 34% and 35% for the six-month
periods ended June 30, 2000 and 2001, respectively.

         VARIABILITY OF FUTURE OPERATING RESULTS In 1998, the Company adopted a
new business model that broadened its services and expanded its customer base.
The favorable results reported for the third quarter of 1999 reflected the first
profitable quarter for this business model. That success continued into the
fourth quarter of 1999 and was interrupted, in the first quarter of 2000, only
by the extra expenses and disruption incurred to relocate the Company to its new
headquarters and lab facility in Houston during January of 2000. The profitable
trend continued into the third quarter of 2000 although earnings were somewhat
lower due to the recruiting expenses explained in the sales, general and
administrative section above. In the first quarter of 2001, the Company began a
reengineering process to significantly enhance productivity in its lab
operations. These enhancements were a combination of process changes made
possible by the addition of new automated equipment. This equipment, which cost
approximately $263,000, is designed to increase operating efficiency and
profitability. The changes made to production methods in the first quarter were
significant and required a considerable amount of development time and cost to
accomplish. These development costs were the principal reason for the higher
than normal cost of services in the first quarter of 2001. These development
costs combined with the additional selling expenses were the main contributors
to the loss sustained in the quarter ended June 30, 2001. Management believes
these changes will enable the Company to significantly increase revenue and
profitability in the future. As the Company continues to grow, it expects to
further automate its processes in order to be even more competitive and to
further increase its market share. The Company continues to seek large contracts
and diversify its customer base.


         LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was $372,509 and
($355,092) for the six-month periods ended June 30, 2000 and 2001, respectively.
The negative operating cash flow for the quarter ending June 30, 2001 occurred
primarily as a result of the reengineering costs, acquisition of new equipment
and selling costs described in Variability of Future Operating Results section,
located just above.

         On December 7, 2000, the Company renewed its revolving loan facility
through December 31, 2001, and may now borrow up to $600,000 under the terms of
the new credit line.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, the company borrowed
$92,000 under this facility. On that same day, the advance line feature of this
loan converted to a fixed facility requiring monthly payments over a 36 month
period at the bank's prime rate plus 2%.

         As of June 30, 2001, the Company was not in compliance with some of the
required financial ratios and has obtained a statement from the bank waiving the
missed requirements until September 1, 2001. The bank has placed a restriction
on further advances on the line during the term of the waiver. Management
believes the Company will be in compliance with the required financial ratios on
or before September 1, 2001.

         On March 29, 2001, the Company entered into a capital lease for the
purchase of two additional automated DNA sequencers. Under the terms of the 36
months lease, the Company may purchase this equipment for a nominal amount at
the end of the lease.


                                       8
<PAGE>   11

         On April 3, 2001, the Company entered into a capital lease for the
purchase of a Multiprobe robotic liquid handling system. Under the terms of the
60 months lease, the Company may purchase this system for a nominal amount at
the end of the lease.

         On June 20, 2001, the Company's U.K. office entered into a capital
lease for the purchase of an automated DNA sequencer. Under the terms of the 36
months lease, the Company will become the owner of the goods at the end of the
lease. See note 4 to financial statements for further details of the Company's
borrowing facilities.


         MATERIAL COMMITMENTS. The Company currently has no outstanding material
commitments.


                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         On June 29, 2000 Joel S. Kanter sued the Company in U.S. District Court
for the Southern District of Texas, Houston Division. The Company entered into a
letter of intent with the "Kanter Group" in 1999 providing for Mr. Kanter to
conduct, or invest in, a proposed $1,320,000 private offering of Company stock.
The transaction was not completed by the time specified in the letter of intent
(on or before November 1, 1999) and Mr. Kanter and the Company continued to work
on the offering for a time thereafter. Mr. Kanter alleges the Company did not
allow him to complete the offering and seeks damages for the breach of the
letter of intent and for reliance damages for his expenses following expiration
of the letter of intent. The Company's position is that there was no binding
agreement, that the letter of intent, by its own terms, prevents Kanter from
recovering and that Kanter imposed material conditions to the completion of the
transaction which were not set forth in the letter of intent. The litigation is
in its initial stages of discovery and the Company intends to file a motion for
summary judgment shortly. The Company intends to vigorously defend the lawsuit
and Management believes that it is without merit.

ITEM 2.  CHANGES IN SECURITIES

         Not applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         Not applicable

ITEM 5.  OTHER INFORMATION

         Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         No reports on Form 8-K were filed during the quarter ending June 30,
2001.

Index of Exhibits


           2.1(1)   The Agreement of Merger of November 18, 1994, between Lark
                    Technologies, Inc. and Lark Sequencing Technologies, Inc.
                    providing for the merger of Lark Sequencing Technologies,
                    Inc. into the Company.

           3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

           3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                    as amended.

           4.1(3)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by
                    the Company.


                                       9
<PAGE>   12


         10.13(2)   Agreement entered into by and between the Company and
                    Genomyx Corporation.

         10.14(2)   The portion of the Minutes of the Executive Session of the
                    Meeting of the Board of Directors of the Company held
                    December 8, 1995, establishing and defining the bonus plan
                    for 1996 under which the chief executive officer, chief
                    financial officer, and other employees may receive cash
                    bonuses as part of their compensation.

(1) Incorporated by reference from the Company's Registration Statement on Form
S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit numbering
system used in Form S-4 differed from that used in this Form 10-QSB (8a, 2d, 2c,
6b, 6c, 6d-1, and 6f, respectively).

(2) Incorporated by reference from the Company's Form 10-QSB for the quarterly
period ended March 31, 1996.

(3) Incorporated by reference from the Company's Registration Statement on Form
S-8 dated September 21, 2000, Commission File No. 333-46280.


                                       10
<PAGE>   13


                                   SIGNATURES


In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                           Lark Technologies, Inc.
                                                  (Registrant)



Date August 8, 2001                              /s/ Carl Balezentis
-------------------                        -------------------------------------
                                                    Carl Balezentis
                                           President and Chief Executive Officer



                                       11